Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Metastatic
Real-world clinical outcomes
Sacituzumab govitecan
Second-line
Treatment patterns
Triple-negative breast cancer
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
08
01
2024
accepted:
13
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
21
6
2024
Statut:
aheadofprint
Résumé
Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and limited treatment options. Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is approved for patients with mTNBC who have received ≥ 2 systemic therapies (≥ 1 in the metastatic setting) based on the ASCENT study (NCT02574455). The current study describes real-world SG use and outcomes in patients with mTNBC in the United States. This retrospective, observational study included adult patients with mTNBC from the ConcertAI Patient360™ database who received SG in the second line (2L) and later from April 2020 to May 2022. SG use patterns, effectiveness, and tolerability are described. This analysis included 230 patients (median age 60 years, 26% Black, 17% with ECOG performance status ≥ 2, 66% in community settings; median of 2 prior lines of treatment in the metastatic setting); median follow-up was 7.2 months. Median (95% CI) real-world overall survival was 10.0 (8.3-11.1) months for all patients and 13.9 (9.8-not estimable) months in the 2L subgroup (n = 77). Granulocyte-colony stimulating factor (G-CSF) was administered concomitantly with SG in 134 (58%) patients; 35 (15%) received G-CSF for the first time. Median (IQR) time from SG start to G-CSF use was 8.5 (8.0-29.0) days. Seventeen (7%) patients discontinued SG due to toxicity. Using a real-world, ethnically diverse population of patients with mTNBC presenting with poor prognosis, these data reinforced the findings from ASCENT. In routine clinical practice, SG is an effective treatment in the 2L setting, consistent with treatment guidelines.
Identifiants
pubmed: 38904892
doi: 10.1007/s10549-024-07412-9
pii: 10.1007/s10549-024-07412-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
American Cancer Society (2023) Cancer facts & figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf . Accessed 5 May 2023
Kohler BA, Sherman RL, Howlader N et al (2015) Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv048
doi: 10.1093/jnci/djv048
pubmed: 25825511
pmcid: 4603551
Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38:1346–1366. https://doi.org/10.1200/JCO.19.02309
doi: 10.1200/JCO.19.02309
pubmed: 31928404
Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol 41:3867–3872. https://doi.org/10.1200/JCO.22.02864
doi: 10.1200/JCO.22.02864
pubmed: 37284804
Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
doi: 10.1158/1078-0432.CCR-06-3045
pubmed: 17671126
Franzoi MA, Saude-Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E (2021) Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: an 11-year single institutional experience. Breast 57:86–94. https://doi.org/10.1016/j.breast.2021.03.002
doi: 10.1016/j.breast.2021.03.002
pubmed: 33799232
pmcid: 8044724
Vona-Davis L, Rose DP, Gadiyaram V, Ducatman B, Hobbs G, Hazard H, Kurian S, Abraham J (2014) Breast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian population. J Cancer Epidemiol 2014:170634. https://doi.org/10.1155/2014/170634
doi: 10.1155/2014/170634
pubmed: 24527034
pmcid: 3913201
Zagami P, Carey LA (2022) Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8:95. https://doi.org/10.1038/s41523-022-00468-0
doi: 10.1038/s41523-022-00468-0
pubmed: 35987766
pmcid: 9392735
Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529–1541. https://doi.org/10.1056/NEJMoa2028485
doi: 10.1056/NEJMoa2028485
pubmed: 33882206
TRODELVY® (sacituzumab govitecan-hziy) (2023) [prescribing information]. Gilead Sciences, Inc., Foster City, CA
TRODELVY® (sacituzumab govitecan-hziy) (2023) [summary of product characteristics]. Gilead Sciences Ireland UC, Carrigtwohill, Ireland. ( https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf )
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V2.2024. © National Comprehensive Cancer Network, Inc. (2024) All rights reserved. Accessed 23 May 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Gennari A, Andre F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475–1495. https://doi.org/10.1016/j.annonc.2021.09.019
doi: 10.1016/j.annonc.2021.09.019
pubmed: 34678411
Moy B, Rumble RB, Come SE et al (2021) Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J Clin Oncol 39:3938–3958. https://doi.org/10.1200/JCO.21.01374
doi: 10.1200/JCO.21.01374
pubmed: 34324366
Alaklabi S, Elijah J, Roy AM, Groman A, Gandhi S (2023) Real-world outcomes of sacituzumab govitecan in metastatic breast cancer patients: a single institution experience [abstract]. Oncology 37(suppl 4):9–10
Clark K, Carroll JL, Moreno-Aspitia A et al (2023) Mayo clinic enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer [abstract]. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS22-P4-07-56
doi: 10.1158/1538-7445.SABCS22-P4-07-56
pubmed: 36720042
pmcid: 10071819
Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer. https://doi.org/10.1038/s41416-024-02685-9
doi: 10.1038/s41416-024-02685-9
pubmed: 38658782
pmcid: 11183215
De Moura A, Loirat D, Vaillant S et al (2024) Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. https://doi.org/10.1007/s12282-024-01565-7
doi: 10.1007/s12282-024-01565-7
pubmed: 38600429
Caputo R, Buono G, Piezzo M et al (2024) Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol 14:1362641. https://doi.org/10.3389/fonc.2024.1362641
doi: 10.3389/fonc.2024.1362641
pubmed: 38595817
pmcid: 11002149
Reinisch M, Bruzas S, Spoenlein J et al (2023) Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol 15:17588359231200454. https://doi.org/10.1177/17588359231200454
doi: 10.1177/17588359231200454
pubmed: 37789989
pmcid: 10542232
Centers for Disease Control (2023) International classification of diseases, tenth revision, clinical modification (ICD-10-CM). https://www.cdc.gov/nchs/icd/icd-10-cm.htm . Accessed 24 May 2024
Duma N, Vera Aguilera J, Paludo J et al (2018) Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract 14:e1–e10. https://doi.org/10.1200/JOP.2017.025288
doi: 10.1200/JOP.2017.025288
pubmed: 29099678
Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC (2021) Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open 4:e2133205. https://doi.org/10.1001/jamanetworkopen.2021.33205
doi: 10.1001/jamanetworkopen.2021.33205
pubmed: 34748007
pmcid: 8576580
Grant SR, Lin TA, Miller AB et al (2020) Racial and ethnic disparities among participants in US-based phase 3 randomized cancer clinical trials. JNCI Cancer Spectr. https://doi.org/10.1093/jncics/pkaa060
doi: 10.1093/jncics/pkaa060
pubmed: 33225207
pmcid: 7667997
Hirko KA, Rocque G, Reasor E et al (2022) The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med 20:72. https://doi.org/10.1186/s12916-022-02260-0
doi: 10.1186/s12916-022-02260-0
pubmed: 35151316
pmcid: 8841090
Loree JM, Anand S, Dasari A et al (2019) Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5:e191870. https://doi.org/10.1001/jamaoncol.2019.1870
doi: 10.1001/jamaoncol.2019.1870
pubmed: 31415071
pmcid: 6696743
Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA (2020) Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat 184:559–565. https://doi.org/10.1007/s10549-020-05867-0
doi: 10.1007/s10549-020-05867-0
pubmed: 32808239
pmcid: 7599186
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA (2021) Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther 38:2213–2225. https://doi.org/10.1007/s12325-020-01613-6
doi: 10.1007/s12325-020-01613-6
pubmed: 33491157
pmcid: 8107067